| Wei Luan,Wen-Xin Li. Safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma and pleural effusion. Oncol Transl Med, 2018, 4: 10-12. |
| Safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma and pleural effusion |
| Received:January 07, 2018 Revised:March 29, 2018 |
| View Full Text View/Add Comment Download reader |
| KeyWord:renal cell carcinoma; pleural effusion; multi-kinase inhibitor; endostar |
| Author Name | Affiliation | E-mail | | Wei Luan | Departments of Oncology,Inner Mongolia people's Hospital | luan1977@126.com | | Wen-Xin Li | Departments of Oncology,Inner Mongolia people's Hospital | liwenxin1888@sohu.com |
|
| Hits: 7029 |
| Download times: 8643 |
| Abstract: |
| Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus
endostar treatment in patients with metastatic renal cell carcinoma (mRCC) and pleural effusion.
Methods A total of 10 patients with mRCC (8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC)
with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib
(400 mg, twice daily), while six received sunitinib (50 mg, once daily; 2 weeks on and 1 week off). All
patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar (15 mg on days 1–4 for 1
or 2 weeks).
Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild.
Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both
effective and safe for the treatment of patients with mRCC with pleural effusion, and may control local
symptoms. |
| Close |